Generic Name:
selinexor
Project Status:
Active
Therapeutic Area:
Multiple myeloma
Manufacturer:
FORUS Therapeutics Inc.
Call for patient/clinician input open:
Brand Name:
(TBC)
Project Line:
Reimbursement Review
Project Sub Line:
Pan Canadian Oncology Drug Review
Project Number:
PC0276-000
Call for patient/clinician input closed:
Tumour Type:
Myeloma
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
As per indication to be reviewed by CADTH: In combination with bortezomib (V) and dexamethasone (d) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
In combination with bortezomib (V) and dexamethasone (d) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.